Green Thumb IndustriesGTBIF +1.08%85 EBITDA Margin % is 38.03% as of Mar. 2026, which is 10% above its 10-year median of 34.47. GuruFocus rates GTBIF with a GF Score™ of 85/100 and a GF Value™ of $8.89 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, Green Thumb Industries ranks better than 94.97% on this metric.
Green Thumb Industries (OTCPK:GTBIF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Green Thumb Industries EBITDA Margin % Related Terms
Green Thumb Industries EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Green Thumb Industries's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Green Thumb Industries's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Green Thumb Industries EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Green Thumb Industries's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Green Thumb Industries's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Green Thumb Industries (GTBIF) has a EBITDA Margin % of 38.03% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Green Thumb Industries and its competitors. This is 10% above median its historical median of 34.47. Over the past decade, Green Thumb Industries' EBITDA Margin % has ranged from 1.03 to 42.51. According to the industry distribution chart, Green Thumb Industries ranks #48 out of 955 companies in the Drug Manufacturers industry, placing it in the top 5%.
Is Green Thumb Industries' EBITDA Margin % too high?
Green Thumb Industries' current EBITDA Margin % of 38.03% is 10% above median its 10-year median of 34.47. Over the past 10 years, this metric has ranged from a low of 1.03 to a high of 42.51. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Green Thumb Industries' value of 38.03% is 205.7% above this industry median. Based on the distribution chart, Green Thumb Industries ranks #48 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Green Thumb Industries has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Green Thumb Industries' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Green Thumb Industries ranks #48 out of 955 companies for EBITDA Margin %. This places Green Thumb Industries in the top 5% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.44. Green Thumb Industries' value of 38.03% is 205.7% above this benchmark. Historically, Green Thumb Industries' own EBITDA Margin % has ranged from 1.03 to 42.51 over the past decade. While the company's 10-year median is 34.47 vs. the industry median of 12.44, Green Thumb Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Green Thumb Industries's current EBITDA Margin % of 38.03% is 205.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Green Thumb Industries and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Green Thumb Industries's current EBITDA Margin % is 38.03%, which is 10% above median its own 10-year median of 34.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Green Thumb Industries stock overvalued right now?
Based on GuruFocus' analysis, Green Thumb Industries (GTBIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.89, compared to a current price of $7.47 — trading 16% below its estimated fair value. The current EBITDA Margin % is 38.03%, which is 10% above median its 10-year median of 34.47 and 205.7% above the Drug Manufacturers industry median of 12.44. Green Thumb Industries' overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Green Thumb Industries (GTBIF), the current EBITDA Margin % is 38.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Green Thumb Industries (GTBIF) Overvalued in 2026?
Based on GuruFocus' analysis, Green Thumb Industries stock appears to be undervalued.
The current stock price of $7.47 is trading 16% below its estimated GF Value™ of $8.89.
GuruFocus considers Green Thumb Industries to be Modestly Undervalued.
Key valuation signals for GTBIF:
EBITDA Margin %: 38.03% (10% above median its 10-year median of 34.47)
GF Value™: $8.89 vs. price of $7.47 (16% below fair value)
Industry Position: 205.7% above the Drug Manufacturers median (#48 of 955)
No single metric tells the full story. See the GTBIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Green Thumb Industries is headquartered in Chicago, Illinois, and produces and sells medicinal and recreational cannabis through wholesale and retail channels in the United States. It has a presence in 14 states and operates more than 100 cannabis stores under the brand Rise. GTI is focusing its expansion on limited-license states with large populations, and it does not currently export into the global medical market due to the USA federal prohibition. It offers multiple products under a portfolio of cannabis consumer packaged goods brands, including &Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, Incredibles, and RYTHM.
85GF Score
Get the complete analysis for GTBIF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GTBIF has been successfully added to your 
